

18/5/2

DIALOG(R) File 351:Derwent WPI  
(c) 2001 Derwent Info Ltd. All rts. reserv.

010678777

WPI Acc No: 1996-175732/199618

XRAM Acc No: C96-055505

Fusion protein comprising human serum albumin contg. peptide inserted at arbitrary position - useful for, e.g. inhibiting cancer metastasis

Patent Assignee: ASAHI GLASS CO LTD (ASAG )

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
JP 8053500	A	19960227	JP 94209368	A	19940811	199618 B

Priority Applications (No Type Date): JP 94209368 A 19940811

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
JP 8053500	A	24	C07K-019/00	

Abstract (Basic): JP 8053500 A

A fusion protein, prepared by introducing peptide(s) into at least one arbitrary position in a polypeptide chain of human serum albumin, is new. Also claimed are: (1) a gene (I) encoding the fusion protein; (2) a recombinant vector contg. (I); and (3) a host cell transformed with the vector of (2) and capable of producing the fusion protein.

USE - The gene is used for production of a fusion protein capable of demonstrating its physical activity sufficiently without destruction of the stereostructure of human serum albumin protein.

ADVANTAGE - A fusion protein eg. a fusion protein for inhibiting cancer metastasis, which could be prepared in the prior art only by a combination of a chemical synthetic method and a binding method, can be produced directly and efficiently for the first time by recombinant DNA technology, thus realising the stable supply in industrial scale processes of a fusion protein for inhibiting cancer metastasis as pharmaceuticals.

Dwg.0/8

Title Terms: FUSE; PROTEIN; COMPRISE; HUMAN; SERUM; ALBUMIN; CONTAIN; PEPTIDE; INSERT; ARBITRARY; POSITION; USEFUL; INHIBIT; CANCER; METASTASIS

Derwent Class: B04; D16

International Patent Class (Main): C07K-019/00

International Patent Class (Additional): C12N-001/19; C12N-015/09; C12P-021/02; C12R-001-645

File Segment: CPI